Sanius Health is excited to announce that it has officially launched the HPCC25 x KOL25 Impact and Insights Report: a powerful reflection of the bold ideas, honest conversations, and emerging priorities that defined two of the most significant health innovation events in Europe this year. More than a recap, the report offers a strategic blueprint for where rare and chronic disease care must go next.
Held on 9th May 2025 in Westminster, the Haematology Patient and Carers Congress (HPCC25) and the inaugural KOL25 Forum brought together an extraordinary community of over 1000 patients, 200 clinicians, 100 NHS Trusts, 13 patient organisations, and senior decision-makers from global pharma, biotech, and academia. At its core, the events were designed to dismantle silos; replacing parallel conversations with shared purpose, actionable insights, and system-wide ambition.
The newly published report distils the key themes explored across the day: from real-world data and trial innovation, to AI-powered care personalisation, equitable access, and workforce resilience. It features sharp analysis, speaker commentary, and visual highlights from a packed agenda that included over 15 sessions and keynote addresses by David Probert (CEO, UCLH and Deputy CEO, NHS England), Dr Sue Pavord (President, British Society of Haematology), Helen Rowntree (CEO, Blood Cancer UK), and Brett Hauber (Pfizer).
A standout message across both HPCC25 and KOL25 was the urgent need to elevate investment in the rare condition space. Not just in the form of therapeutic innovation, but through better infrastructure, deeper research partnerships, and long-term support for both patients and the people working to serve them. The events positioned patient-led data, co-designed pathways, and integrated systems as non-negotiables for any meaningful progress.
This was also a moment to connect ambition with delivery. Closed-door sessions at KOL25 enabled senior leaders across medical affairs, market access, R&D, and regulatory policy to align on the challenges and opportunities facing the future of real-world evidence, cross-sector partnerships, and care innovation at scale.
Orlando Agrippa, CEO of Sanius Health, described the events as “a turning point for how we define value, not in isolation, but through collaboration. What we’ve captured in this report is not just what happened, but what must happen next.”
For anyone involved in delivering innovation in haematology or rare disease care, from pharma leadership and clinical research to policy design and advocacy, this report is essential reading. It reflects where the sector is headed, what’s now expected, and how those leading the charge can work together to accelerate progress.
To view the report, please visit https://shorturl.at/DS4hY
Looking ahead, Sanius Health is set to scale its investment even further, expanding its technology infrastructure, research collaborations, and patient support across rare and chronic conditions. Building on the momentum of HPCC25 and KOL25, next year’s event will be bigger, bolder, and even more connected. For those interested in attending, speaking, or partnering, now is the time to get involved.
To secure your place or explore bespoke partnership opportunities, please contact the Sanius Health team at info@saniushealth.com.
